

MARSHALL, GERSTEIN & BORUN
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

March 5, 2003

FACSIMILE TRANSMISSION SHEET

TO Examiner Hope
Robinson
COMPANY U.S. Patent &
Trademark Office
FAX NO. 703/746-5128
PHONE NO.

FROM: Mark Hopkins, Ph.D.

EXTENSION: 637

PAGES (INCLUDING THIS PAGE): 3

CLIENT NO: 28594

MATTER NO: 35007A

PLEASE CONFIRM RECEIPT: YES

COUNTRY CODE: US

MESSAGE: For U.S. Patent Application Serial No. 09/400,769: INFORMAL SUBMISSION--
NOT FOR ENTRY INTO FILE

Please contact Terre Robertson at (312) 474-6825 if you do not receive all of the pages in good condition.

The material of this transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

312-474-6637

INFORMAL SUBMISSION NOT FOR ENTRY INTO FILE

To: Examiner Hope Robinson
 From: Mark Hopkins
 Date: March 5, 2003
 Re: USSN 09/400,769

AMENDMENTS

In the Claims:

Claim 1 will be amended as shown below:

1. (Currently amended) A method for treating a patient suffering from one or more insulin related ailments selected from the group consisting of hyperglycemia, hypoglycemia, diabetes mellitus, insulinomas, insulin and hypoglycaemic drug overdose, gastric dumping syndrome and congenital hyperinsulinism, alzheimers disease, which method comprises the step of: administering to a patient in need thereof a therapeutically effective amount of a non-peptidyl compound [that is a biological modulator of insulin activity,] which [compound] possesses one or more ionic and hydrophobic chemical moieties spatially located so as to mimic the spatial location of at least an ionic or a hydrophobic amino acid residue of insulin, wherein said compound is an insulin receptor agonist or antagonist, [which amino acids are associated with the binding of insulin to its receptor].

or alternately

1. (Currently amended) A method for treating a patient suffering from one or more insulin related ailments selected from the group consisting of hyperglycemia, hypoglycemia, diabetes mellitus, insulinomas, insulin and hypoglycaemic drug overdose, gastric dumping syndrome and congenital hyperinsulinism, alzheimers disease, which method comprises the step of: administering to a patient in need thereof a therapeutically effective amount of a non-peptidyl compound [that is a biological modulator of insulin activity,] which [compound] possesses one or more ionic and hydrophobic chemical moieties spatially located so as to mimic the spatial location of at least an ionic or a hydrophobic amino acid residue of insulin, wherein said compound binds to an [which amino acids are associated with the binding of] insulin [to its] receptor.